Clinical trials: Sham-controlled
Acute Otitis Externa, Swimmer's Ear
Phase 3 Study of OTO-201 in Acute Otitis Externa
This is a prospective, randomized, double-blind, sham-controlled, multicenter, Phase 3 study in which eligible subjects with acute otitis externa (AOE) will be randomized to receive a single administration of either 12 mg OTO-201…
- Trial name
- NCT02801370
- Testing
- 12 mg ciprofloxacin
- Where
- 2 sites in United States, Canada
- Volunteers
- 262 people
- Sponsor
- Otonomy, Inc.
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03319849
- Testing
- NT-501
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 119 people
- Sponsor
- Neurotech Pharmaceuticals
Concussion, Mild
Pro-2-Cool Pivotal Trial II
This study is being conducted to determine the clinical safety and efficacy of Pro-2-Cool mediated head and neck cooling when applied after concussion and improved symptomatology among adolescent athletes as quantified by…
- Trial name
- NCT06929923
- Testing
- Pro2Cool Device
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- TecTraum Inc.
Migraine Without Aura, Migraine With Aura
Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT03361423
- Testing
- Nerivio Migra-1 active device
- Where
- 12 sites in United States, Israel
- Volunteers
- 296 people
- Sponsor
- Theranica
Age-Related Maculopathy
Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis
SUMMARY Age-related macular degeneration (AMD) is the leading cause of late onset visual impairment and legal blindness in people 65 years of age or older in the United States.
- Trial name
- RHEO-AMD (NCT00460967)
- Testing
- Rheopheresis
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 325 people
- Sponsor
- OccuLogix
Diabetic Macular Edema
A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate the initial safety of intravitreal (IVT) LKA651 and potential for use alone or in combination with Ranibizumab ophthalmic solution (Lucentis®) for the treatment of Diabetic Macular Edema…
- Trial name
- NCT02281292
- Testing
- LKA651 ophthalmic solution, Ranibizumab ophthalmic solution
- Sponsor
- Alcon Research
Macular Degeneration
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
- Trial name
- NCT00087763
- Testing
- Macugen ™ (pegaptanib sodium injection)
- Volunteers
- 135 people
- Sponsor
- Eyetech Pharmaceuticals
Degenerative Disc Disease, Disc Degeneration
ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
VIA Disc NP is an off-the-shelf minimally processed human nucleus pulposus tissue allograft intended to supplement degenerated intervertebral discs.
- Conditions
- Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
- Trial name
- ASCEND (NCT06615505)
- Testing
- VIA Disc NP
- Where
- 5 sites in Australia
- Volunteers
- 121 people
- Sponsor
- VIVEX Biologics, Inc.
Insomnia
Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02)
The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.
- Trial name
- NCT05809544
- Testing
- WELT-IP
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- WELT corp
Rhegmatogenous Retinal Detachment - Macula Off
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment…
- Trial name
- NCT05730218
- Testing
- ONL1204 Ophthalmic Solution
- Where
- 36 sites in United States
- Volunteers
- 136 people
- Sponsor
- ONL Therapeutics
Uveitic Macular Edema
Vamikibart in Participants With Uveitic Macular Edema
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
- Trial name
- Sandcat (NCT05642325)
- Testing
- Vamikibart
- Where
- 94 sites in United States, Argentina and 17 more
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for diabetic macular edema.
- Trial name
- NCT01411254
- Testing
- Betamethasone Microsphere (DE-102） Low Dose, Betamethasone Microsphere (DE-102） High Dose
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Chronic Rhinitis
RhinAer Procedure for Treatment of Chronic Rhinitis Study
The purpose of this study is to compare the RhinAer procedure with radiofrequency (RF) energy to sham procedure for treatment of chronic rhinitis.
- Trial name
- RHINTRAC (NCT04533438)
- Testing
- RhinAer Stylus
- Where
- 13 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Aerin Medical
Visual Display Users With Previously Undiagnosed Dry Eye
Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users
Two study arms - sham and treatment; There will be a cross over of the sham group to the treatment group at day 15.
- Trial name
- NCT04763018
- Testing
- iTEAR100
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Olympic Ophthalmics, Inc.
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
- Trial name
- NCT06430385
- Testing
- ION440
- Where
- 12 sites in United States, Austria and 3 more
- Volunteers
- 48 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Diabetic Neuropathies, Pain
The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy
This study is intended to demonstrate that exposure to a high intensity, DC electromagnetic field, as supplied by the investigational device known as the Molecular Magnetic Energizer (MME), will create a clinically meaningful…
- Conditions
- Diabetic Neuropathies, Pain, Neuralgia
- Trial name
- NCT00134524
- Testing
- MME procedure
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Advanced Magnetic Research Institute International
Glaucoma, Angle-closure, Primary, Acute
Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)
This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug.
- Trial name
- NCT01965106
- Testing
- QPI-1007 Injection
- Where
- 8 sites in United States, Singapore and 1 more
- Volunteers
- 46 people
- Sponsor
- Quark Pharmaceuticals
Diabetic Foot Ulcers
A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers
The Sponsor of this study, SANUWAVE, Inc., has developed an investigational device known as the dermaPACE® (Pulsed Acoustic Cellular Expression) device for the possible treatment of diabetic foot ulcers.
- Trial name
- NCT01824407
- Testing
- Electrohydraulic-generated shock wave
- Where
- 19 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- SANUWAVE, Inc.
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RISE (NCT00473330)
- Testing
- Ranibizumab
- Volunteers
- 377 people
- Sponsor
- Genentech, Inc.